Evidence map›Paper›PMID 26458765›Full record

ArticleThe American journal of pathology2015

Differential Requirements for IL-17A and IL-22 in Cecal versus Colonic Inflammation Induced by Helicobacter hepaticus.

Peter J Morrison, Sarah J Ballantyne, Sandy J Macdonald, John W J Moore, David Jenkins, Jill F Wright, Lynette A Fouser, Marika C Kullberg

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Deletion of IL-17A EnhancesJournal of inflammation research · 2022
    Article
  5. Article
  6. Male-Dependent Promotion of Colitis in 129International journal of molecular sciences · 2020
    Article
  7. The development of colitis in Il10Mucosal immunology · 2020
    Article
  8. The role of IL-22 in intestinal health and disease.The Journal of experimental medicine · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Peter J MorrisonCentre for Immunology and Infection, Department of Biology and Hull York Medical School, University of York, York, United Kingdom.
Sarah J BallantyneCentre for Immunology and Infection, Department of Biology and Hull York Medical School, University of York, York, United Kingdom.
Sandy J MacdonaldCentre for Chronic Diseases and Disorders, Department of Biology, University of York, York, United Kingdom.
John W J MooreCentre for Immunology and Infection, Department of Biology and Hull York Medical School, University of York, York, United Kingdom.
David JenkinsCentre for Immunology and Infection, Department of Biology and Hull York Medical School, University of York, York, United Kingdom.
Jill F WrightDevelopment Operations, Pfizer Biotherapeutics Research and Development, Cambridge, Massachusetts.
Lynette A FouserDevelopment Operations, Pfizer Biotherapeutics Research and Development, Cambridge, Massachusetts.
Marika C KullbergCentre for Immunology and Infection, Department of Biology and Hull York Medical School, University of York, York, United Kingdom. Electronic address: marika.kullberg@york.ac.uk.
University of York · GBPfizer (United States) · US

Funding

Medical Research Council G0700806
6 · The paper itself

Abstract

Type 17 helper T-cell cytokines have been implicated in the pathogenesis of inflammatory bowel disease, a chronic condition affecting the gastrointestinal tract, but information regarding their contribution to pathology in different regions of the gut is lacking. By using a murine model of bacteria-induced typhlocolitis, we investigated the role of IL-17A, IL-17F, and IL-22 in cecal versus colonic inflammation. Cecal, but not colonic, pathology in C57BL/6 mice inoculated with Helicobacter hepaticus plus anti-IL-10 receptor (IL-10R) monoclonal antibody was exacerbated by co-administration of anti-IL-17A monoclonal antibody, suggesting a disease-protective role for IL-17A in the cecum. In contrast, anti-IL-17F had no effect on H. hepaticus-induced intestinal pathology. Neutralization of IL-22 prevented the development of colonic, but not cecal, inflammation in H. hepaticus-infected anti-IL-10R-treated mice, demonstrating a pathogenic role for IL-22 in the colon. Analysis of transcript levels revealed differential expression of IL-22R, IL-22 binding protein, and IL-23R between cecum and colon, a finding that may help explain why these tissues respond differently after anti-IL-22 treatment. Analysis of microarray data from healthy human intestine further revealed significant differences in cytokine receptor transcript levels (including IL-22RA1 and IL-23R) in distinct parts of the human gut. Together, our findings demonstrate that individual type 17 helper T-cell cytokines can have proinflammatory or anti-inflammatory effects in different regions of the intestine, an observation that may have implications for interventions against human inflammatory bowel disease.

Indexed as

Helicobacter hepaticusAnimalsAntibodies, MonoclonalColitisFemaleGene ExpressionHelicobacter InfectionsHumansInterleukin-17Interleukin-22InterleukinsIntestinesMice, Inbred C57BLReceptors, CytokineRNA, MessengerTyphlitisAntibodies, MonoclonalInterleukin-17Interleukin-22InterleukinsReceptors, CytokineRNA, Messenger

Identifiers

PMID26458765
PMCPMC4729236
OpenAlexW2174729051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.